<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666454</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002708-38</org_study_id>
    <nct_id>NCT04666454</nct_id>
  </id_info>
  <brief_title>BROKEN-SWEDEHEART-Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome</brief_title>
  <official_title>Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to document an optimized pharmacologic treatment for patients with&#xD;
      Takotsubo Syndrome. There is currently no published documentation in a large number of&#xD;
      patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients&#xD;
      registered in SWEDEHEART will be included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Multicentre, registry-based, open-label, randomized controlled trial with 2 × 2 factorial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Randomization 1: First co-primary endpoint: Wall motion score index (defined as the semi-quantitative score according to the American Society of Echocardiography)</measure>
    <time_frame>at 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomization 1: Second co-primary endpoint: The occurrence of the composite of death, cardiac arrest, or the need for cardiac mechanical assist device, or re-hospitalization for heart failure or ejection fraction &lt;50%</measure>
    <time_frame>within 30 days respectively at 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomization 2: The occurrence of any thromboembolic event (defined as ischemic stroke, peripheral arterial embolization or myocardial infarction) or death, or the presence of a cardiac thrombus, as assessed by echocardiography</measure>
    <time_frame>within 30 days respectively at 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: The hierarchical occurrence (in descending order of importance) of time to death, time to cardiac assist device, time to cardiac arrest and ejection fraction &lt;50%</measure>
    <time_frame>all time to the first occurrence within 30 days respectively at 72 hours (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Ejection fraction</measure>
    <time_frame>at 72 hours (continuous)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Any sustained ventricular tachycardia or fibrillation</measure>
    <time_frame>within 72 hours (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Any high-grade atrioventricular block or sinus arrest</measure>
    <time_frame>within 72 hours (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Need for cardiac assist device</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Death</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 1: Stroke</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 2: Presence of cardiac thrombus</measure>
    <time_frame>at 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 2: Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria minor or major</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 2: Bleeding Academic Research Consortium (BARC) grade 2-5</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 2: BARC grade 3-5</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization 2: Any blood transfusion</measure>
    <time_frame>within 30 days (binary)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Takotsubo Syndrome</condition>
  <arm_group>
    <arm_group_label>Randomisation 1: Adenosine and Dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adenosine infusion 70 µg/kg/min for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 72 hours or at any subsequent echocardiographic examination, or for 30 Days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation 1: Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation 2: Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 72 hours or any subsequent echocardiographic examination, or for 30 Days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation 2: No anticoagulant therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine infusion 70 µg/kg/min for 3 hours.</description>
    <arm_group_label>Randomisation 1: Adenosine and Dipyridamole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole 200 mg</intervention_name>
    <description>200 mg b.i.d</description>
    <arm_group_label>Randomisation 1: Adenosine and Dipyridamole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 mg Oral Tablet</intervention_name>
    <description>5mg b.i.d</description>
    <arm_group_label>Randomisation 2: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome</intervention_name>
    <description>This treatment will vary depending on local routines and the degree of adherence to the recommendations.</description>
    <arm_group_label>Randomisation 1: Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. A clinical diagnosis of Takotsubo syndrome (TS)&#xD;
&#xD;
          3. Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous randomization in the study&#xD;
&#xD;
          2. Any contra-indication for treatment with adenosine or dipyridamole (including AV-block&#xD;
             II and III, sick sinus syndrome in patients who do not have a functioning pacemaker,&#xD;
             unstable angina, ongoing treatment with dipyridamole)&#xD;
&#xD;
          3. Any concomitant condition resulting in a life expectancy of less than one month&#xD;
&#xD;
          4. Previous myocardial infarction&#xD;
&#xD;
          5. Previously diagnosed left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          6. Known cardiomyopathy&#xD;
&#xD;
          7. Known hemodynamically significant valve disease (moderate or severe aortic/mitral&#xD;
             regurgitation or stenosis)&#xD;
&#xD;
          8. Heart transplant or left ventricular assist device recipient&#xD;
&#xD;
          9. Most recent (within the most recent 3 months) haemoglobin &lt;100 g/L&#xD;
&#xD;
         10. Systolic blood pressure &lt;80 mm Hg at screening&#xD;
&#xD;
         11. Estimated glomerular filtration rate &lt;30 mL/min/1.73m2&#xD;
&#xD;
         12. Current dialysis&#xD;
&#xD;
         13. Pregnancy or of childbearing potential who is not sterilized or is not using a&#xD;
             medically accepted form of contraception&#xD;
&#xD;
         14. Not suitable in the opinion of the investigator due to severe or terminal comorbidity&#xD;
             with poor prognosis, or characteristics that may interfere with adherence to the&#xD;
             study-protocol&#xD;
&#xD;
        Specific subject exclusion criteria (Randomization 2)&#xD;
&#xD;
          1. Any contra-indication for anticoagulant treatment.&#xD;
&#xD;
          2. Current indication for treatment with, anticoagulant or dual antiplatelet therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elmir Omerovic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elmir Omerovic, MD PhD</last_name>
    <phone>31 3421000</phone>
    <phone_ext>+46</phone_ext>
    <email>elmir@wlab.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Björn Redfors, MD, PhD</last_name>
    <phone>31 3421000</phone>
    <phone_ext>+46</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Department of Cardiology</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To be decided.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>To be decided</ipd_time_frame>
    <ipd_access_criteria>To be decided (TBD)</ipd_access_criteria>
    <ipd_url>https://TBD</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

